Spectrum Pharmaceuticals, Inc.  

(Public, NASDAQ:SPPI)   Watch this stock  
Find more results for SPPI
-0.11 (-1.83%)
Feb 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.68 - 6.03
52 week 3.21 - 7.74
Open 6.03
Vol / Avg. 902,291.00/553,335.00
Mkt cap 467.40M
P/E     -
Div/yield     -
EPS -0.78
Shares 80.56M
Beta 1.22
Inst. own 67%
Mar 7, 2017
Q4 2016 Spectrum Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -52.27% -31.24%
Operating margin -47.90% -25.06%
EBITD margin - -1.05%
Return on average assets -15.94% -11.17%
Return on average equity -28.77% -21.74%
Employees 212 -
CDP Score - -


11500 S Eastern Ave Ste 240
HENDERSON, NV 89052-5576
United States - Map
+1-702-8356300 (Phone)
+1-702-2607405 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Spectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has approximately six approved oncology/hematology products that target different types of non-Hodgkin's lymphoma (NHL), metastatic colorectal cancer, acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). It also has two drugs in late-stage development: SPI-2012, which is being developed for chemotherapy-induced neutropenia in patients with breast cancer, and EOQUIN, which is being developed for immediate intravesical instillation post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. It has a product portfolio consisting of both commercial-stage and development-stage products that address various cancer types. Its commercialized products include FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ and EVOMELA. Its other products include SPI-2012, POZIOTINIB and EOQUIN.

Officers and directors

Rajesh C. Shrotriya M.D. Chairman of the Board, Chief Executive Officer
Age: 71
Bio & Compensation  - Reuters
Joseph W. Turgeon President, Chief Operating Officer
Age: 57
Bio & Compensation  - Reuters
Kurt A. Gustafson Chief Financial Officer, Executive Vice President
Age: 48
Bio & Compensation  - Reuters
Luigi Lenaz M.D. Lead Independent Director
Age: 74
Bio & Compensation  - Reuters
Gilles R. Gagnon Director
Age: 61
Bio & Compensation  - Reuters
Raymond Wayne Cohen Independent Director
Age: 56
Bio & Compensation  - Reuters
Stuart M. Krassner Independent Director
Age: 79
Bio & Compensation  - Reuters
Anthony E. Maida III, Ph.D. Independent Director
Age: 64
Bio & Compensation  - Reuters